CAMP-dependent protein kinase
From Proteopedia
(Difference between revisions)
| Line 35: | Line 35: | ||
**[[4ntt]] – mPKA (mutant) + ADP<br /> | **[[4ntt]] – mPKA (mutant) + ADP<br /> | ||
**[[2gfc]], [[3dnd]], [[3dne]], [[3kkv]], [[3zo1]], [[3zo2]], [[3zo3]], [[3zo4]], [[4ie9]], [[4ij9]], [[4yxs]], [[4yxr]] - bPKA + peptide inhibitor<br /> | **[[2gfc]], [[3dnd]], [[3dne]], [[3kkv]], [[3zo1]], [[3zo2]], [[3zo3]], [[3zo4]], [[4ie9]], [[4ij9]], [[4yxs]], [[4yxr]] - bPKA + peptide inhibitor<br /> | ||
| - | **[[4wih]] - | + | **[[4wih]], [[5lcp]], [[5lcq]], [[5lcr]], [[5lct]], [[5lcu]] - haPKA + peptide inhibitor – hamster<br /> |
| + | **[[5n1f]], [[5n1g]], [[5n1h]], [[5n3g]], [[5n3h]], [[5n3i]], [[5n3j]], [[5n3k]], [[5n3l]], [[5n3m]], [[5n3n]], [[5n3o]], [[5n3p]], [[5n3q]], [[5n3r]], [[5n3s]], [[5n3t]] - haPKA + fragment molecule<br /> | ||
**[[2gng]], [[4axa]], [[4c33]], [[4c34]], [[4c35]], [[4c36]], [[4c37]], [[4c38]] - bPKA (mutant) + peptide inhibitor<br /> | **[[2gng]], [[4axa]], [[4c33]], [[4c34]], [[4c35]], [[4c36]], [[4c37]], [[4c38]] - bPKA (mutant) + peptide inhibitor<br /> | ||
**[[3mvj]], [[3oog]], [[3poo]], [[3vqh]], [[5j5x]], [[5izj]], [[5izf]], [[5bx7]], [[5bx6]], [[4ujb]], [[4uja]], [[4uj9]], [[4uj2]], [[4uj1]] - hPKA + peptide inhibitor<br /> | **[[3mvj]], [[3oog]], [[3poo]], [[3vqh]], [[5j5x]], [[5izj]], [[5izf]], [[5bx7]], [[5bx6]], [[4ujb]], [[4uja]], [[4uj9]], [[4uj2]], [[4uj1]] - hPKA + peptide inhibitor<br /> | ||
| Line 61: | Line 62: | ||
**[[2gnh]], [[2gni]], [[2gnj]], [[2gnl]], [[2jdv]], [[2uvx]], [[2uvy]], [[2uvz]], [[2uw0]], [[2uw3]], [[2uw4]], [[2uw5]], [[2uw6]], [[2uw7]], [[2uw8]], [[2vnw]], [[2vny]], [[2vo0]], [[2vo3]], [[2vo6]], [[2vo7]] - bPKA (mutant) + peptide inhibitor + inhibitor<br /> | **[[2gnh]], [[2gni]], [[2gnj]], [[2gnl]], [[2jdv]], [[2uvx]], [[2uvy]], [[2uvz]], [[2uw0]], [[2uw3]], [[2uw4]], [[2uw5]], [[2uw6]], [[2uw7]], [[2uw8]], [[2vnw]], [[2vny]], [[2vo0]], [[2vo3]], [[2vo6]], [[2vo7]] - bPKA (mutant) + peptide inhibitor + inhibitor<br /> | ||
**[[1ydr]], [[1yds]], [[1ydt]] - bPKA + peptide inhibitor + inhibitor<br /> | **[[1ydr]], [[1yds]], [[1ydt]] - bPKA + peptide inhibitor + inhibitor<br /> | ||
| - | **[[2gu8]], [[3l9l]], [[3ovv]], [[3owp]], [[3oxt]], [[3p0m]] - hPKA catalytic subunit + peptide inhibitor + inhibitor<br /> | + | **[[2gu8]], [[3l9l]], [[3ovv]], [[3owp]], [[3oxt]], [[3p0m]], [[5uzk]] - hPKA catalytic subunit + peptide inhibitor + inhibitor<br /> |
**[[3nx8]] - hPKA catalytic subunit + peptide inhibitor + phenol<br /> | **[[3nx8]] - hPKA catalytic subunit + peptide inhibitor + phenol<br /> | ||
**[[3l9m]], [[3l9n]], [[3ama]], [[3amb]] - hPKA (mutant) + peptide inhibitor + inhibitor<br /> | **[[3l9m]], [[3l9n]], [[3ama]], [[3amb]] - hPKA (mutant) + peptide inhibitor + inhibitor<br /> | ||
| Line 71: | Line 72: | ||
**[[1q8t]], [[1q8u]], [[1q8w]]- bPKA + peptide inhibitor + rho-kinase inhibitor<br /> | **[[1q8t]], [[1q8u]], [[1q8w]]- bPKA + peptide inhibitor + rho-kinase inhibitor<br /> | ||
**[[2gnf]] - bPKA (mutant) + peptide inhibitor + rho-kinase inhibitor<br /> | **[[2gnf]] - bPKA (mutant) + peptide inhibitor + rho-kinase inhibitor<br /> | ||
| + | **[[5vib]] - bPKA + peptide inhibitor + benzothiazole derivative inhibitor<br /> | ||
| + | **[[5vbh]], [[5vi9]] - bPKA (mutant) + peptide inhibitor + benzothiazole derivative inhibitor<br /> | ||
**[[1sve]], [[1svg]], [[1svh]], [[1veb]] - bPKA + detergent + peptide inhibitor + azepane derivative<br /> | **[[1sve]], [[1svg]], [[1svh]], [[1veb]] - bPKA + detergent + peptide inhibitor + azepane derivative<br /> | ||
**[[2c1a]], [[2c1b]] - bPKA + peptide inhibitor + isoquinoline-sulfamide inhibitor<br /> | **[[2c1a]], [[2c1b]] - bPKA + peptide inhibitor + isoquinoline-sulfamide inhibitor<br /> | ||
| Line 76: | Line 79: | ||
**[[2uzt]], [[2uzu]], [[2uzv]], [[2uzw]] - bPKA + peptide inhibitor + indazole-pyridine inhibitor<br /> | **[[2uzt]], [[2uzu]], [[2uzv]], [[2uzw]] - bPKA + peptide inhibitor + indazole-pyridine inhibitor<br /> | ||
**[[2jdt]] - bPKA (mutant) + peptide inhibitor + isoquinoline-sulfamide inhibitor<br /> | **[[2jdt]] - bPKA (mutant) + peptide inhibitor + isoquinoline-sulfamide inhibitor<br /> | ||
| + | **[[5mhi]], [[5n1d]], [[5n1e]], [[5n1k]], [[5n1l]], [[5n1m]], [[5n1n]], [[5n1o]], [[5n32]], [[5n33]], [[5n36]], [[5n37]], [[5n39]], [[5n3a]], [[5n3b]], [[5n3c]], [[5n3d]], [[5n3e]], [[5n3f]], [[5n7p]], [[5n7u]] - haPKA + peptide inhibitor + fragment molecule<br /> | ||
*PKA regulatory subunit | *PKA regulatory subunit | ||
| Line 93: | Line 97: | ||
**[[2drn]], [[2h9r]] - rPKA II-α dimerization-anchoring domain + A-kinase anchoring protein peptide – NMR<br /> | **[[2drn]], [[2h9r]] - rPKA II-α dimerization-anchoring domain + A-kinase anchoring protein peptide – NMR<br /> | ||
**[[2izx]], [[2izy]], [[4zp3]] - hPKA II-α + A-kinase anchoring protein peptide<br /> | **[[2izx]], [[2izy]], [[4zp3]] - hPKA II-α + A-kinase anchoring protein peptide<br /> | ||
| - | **[[3im4]] - bPKA I-α + A-kinase anchoring protein peptide<br /> | + | **[[3im4]], [[5hvz]] - bPKA I-α + A-kinase anchoring protein peptide<br /> |
**[[2hwn]] - rPKA II-α + A-kinase binding peptide<br /> | **[[2hwn]] - rPKA II-α + A-kinase binding peptide<br /> | ||
**[[4jva]] – rPKA II-β + cAMP analog<br /> | **[[4jva]] – rPKA II-β + cAMP analog<br /> | ||
**[[4jv4]] – bPKA I-α + cAMP analog<br /> | **[[4jv4]] – bPKA I-α + cAMP analog<br /> | ||
**[[2kyg]] - hPKA II-α + CBFA2T1<br /> | **[[2kyg]] - hPKA II-α + CBFA2T1<br /> | ||
| + | **[[5kjx]] - hPKA I-α + cAMP<br /> | ||
| + | **[[5kjy]], [[5kjz]] - hPKA I-α (mutant) + cAMP<br /> | ||
**[[3plq]] - bPKA I-α + cAMP derivative<br /> | **[[3plq]] - bPKA I-α + cAMP derivative<br /> | ||
**[[5t3n]] - PfPKA + cAMP derivative – ''Plasmodium falciparum''<br /> | **[[5t3n]] - PfPKA + cAMP derivative – ''Plasmodium falciparum''<br /> | ||
Revision as of 09:10, 4 April 2018
| |||||||||||
3D structures of cAMP-dependent protein kinase
Updated on 04-April-2018
References
- ↑ Bastidas AC, Wu J, Taylor SS. Molecular Features of Product Release for the PKA Catalytic Cycle. Biochemistry. 2014 Aug 8. PMID:25077557 doi:http://dx.doi.org/10.1021/bi500684c
- ↑ Brown SH, Cheng CY, Saldanha SA, Wu J, Cottam HB, Sankaran B, Taylor SS. Implementing Fluorescence Anisotropy Screening and Crystallographic Analysis to Define PKA Isoform-Selective Activation by cAMP Analogs. ACS Chem Biol. 2013 Sep 10. PMID:23978166 doi:10.1021/cb400247t
